<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Thompson SA</submitter><funding>AustinPx</funding><pagination>1281</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10215938</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(5)</volume><pubmed_abstract>This study compares the effects of pre-processing multiple polymers together to form a single-phase polymer alloy prior to amorphous solid dispersion formulation. KinetiSol compounding was used to pre-process a 1:1 (&lt;i>w&lt;/i>/&lt;i>w&lt;/i>) ratio of hypromellose acetate succinate and povidone to form a single-phase polymer alloy with unique properties. Ivacaftor amorphous solid dispersions comprising either a polymer, an unprocessed polymer blend, or the polymer alloy were processed by KinetiSol and examined for amorphicity, dissolution performance, physical stability, and molecular interactions. A polymer alloy ivacaftor solid dispersion with a drug loading of 50% &lt;i>w&lt;/i>/&lt;i>w&lt;/i> was feasible versus 40% for the other compositions. Dissolution in fasted simulated intestinal fluid revealed that</pubmed_abstract><journal>Biomedicines</journal><pubmed_title>Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution.</pubmed_title><pmcid>PMC10215938</pmcid><funding_grant_id>N/A</funding_grant_id><pubmed_authors>Williams RO</pubmed_authors><pubmed_authors>Miller DA</pubmed_authors><pubmed_authors>Thompson SA</pubmed_authors><pubmed_authors>Kucera SU</pubmed_authors><pubmed_authors>Davis DA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution.</name><description>This study compares the effects of pre-processing multiple polymers together to form a single-phase polymer alloy prior to amorphous solid dispersion formulation. KinetiSol compounding was used to pre-process a 1:1 (&lt;i>w&lt;/i>/&lt;i>w&lt;/i>) ratio of hypromellose acetate succinate and povidone to form a single-phase polymer alloy with unique properties. Ivacaftor amorphous solid dispersions comprising either a polymer, an unprocessed polymer blend, or the polymer alloy were processed by KinetiSol and examined for amorphicity, dissolution performance, physical stability, and molecular interactions. A polymer alloy ivacaftor solid dispersion with a drug loading of 50% &lt;i>w&lt;/i>/&lt;i>w&lt;/i> was feasible versus 40% for the other compositions. Dissolution in fasted simulated intestinal fluid revealed that</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-04T20:56:33.141Z</modification><creation>2025-04-04T20:56:33.141Z</creation></dates><accession>S-EPMC10215938</accession><cross_references><pubmed>37238952</pubmed><doi>10.3390/biomedicines11051281</doi></cross_references></HashMap>